{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:06:16Z","timestamp":1789189576043,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Government of Japan Ministry of Health Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jacl.2026.08.010","type":"journal-article","created":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T21:42:24Z","timestamp":1787521344000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A \u226520% increase in circulating Lp(a) after the commencement of statins, and subsequent risks of atherosclerotic cardiovascular diseases in patients with coronary artery disease"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3543-4577","authenticated-orcid":false,"given":"Shuhei","family":"Fujita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6307-5593","authenticated-orcid":false,"given":"Yu","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5803-5324","authenticated-orcid":false,"given":"Naoto","family":"Kuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Mitsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5162-4783","authenticated-orcid":false,"given":"Kota","family":"Murai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Iwai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0710-0870","authenticated-orcid":false,"given":"Kenichiro","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Matama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2706-4317","authenticated-orcid":false,"given":"Masashi","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4162-2036","authenticated-orcid":false,"given":"Fumiyuki","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9009-7234","authenticated-orcid":false,"given":"Yasuhide","family":"Asaumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Tsujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruo","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jacl.2026.08.010_bib1","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.08.010_bib2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2147\/VHRM.S266244","article-title":"Elevated lipoprotein(a): background, current insights and future potential therapies","volume":"17","author":"Handhle","year":"2021","journal-title":"Vasc Health Risk Manag"},{"issue":"26","key":"10.1016\/j.jacl.2026.08.010_bib3","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jacl.2026.08.010_bib4","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.jacl.2026.08.010_bib5","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1161\/CIRCULATIONAHA.120.045826","article-title":"Lipoprotein(a) in alzheimer, atherosclerotic, cerebrovascular, thrombotic, and valvular disease: Mendelian randomization investigation","volume":"141","author":"Larsson","year":"2020","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jacl.2026.08.010_bib6","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1161\/ATVBAHA.116.308011","article-title":"Prevalence of elevated Lp(a) mass levels and patient thresholds in 532,359 patients in the United States","volume":"36","author":"Varvel","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.jacl.2026.08.010_bib7","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1253\/circj.CJ-24-0383","article-title":"Impact of high lipoprotein(a) levels on delayed wound healing in patients with chronic limb-threatening ischemia after peripheral endovascular therapy","volume":"89","author":"Tomoi","year":"2025","journal-title":"Circ J"},{"issue":"6","key":"10.1016\/j.jacl.2026.08.010_bib8","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1253\/circj.CJ-20-0051","article-title":"Lipoprotein(a) and cardiovascular diseases \u2013 revisited","volume":"84","author":"Jang","year":"2020","journal-title":"Circ J"},{"issue":"24","key":"10.1016\/j.jacl.2026.08.010_bib9","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"issue":"24","key":"10.1016\/j.jacl.2026.08.010_bib10","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1093\/eurheartj\/ehz505","article-title":"Statins increase Lp(a) plasma level: is this clinically relevant?","volume":"41","author":"Pirillo","year":"2020","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.jacl.2026.08.010_bib11","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1253\/circj.CJ-19-0133","article-title":"JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome","volume":"83","author":"Kimura","year":"2019","journal-title":"Circ J"},{"issue":"9","key":"10.1016\/j.jacl.2026.08.010_bib12","doi-asserted-by":"crossref","first-page":"846","DOI":"10.5551\/jat.GL2017","article-title":"Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017","volume":"25","author":"Kinoshita","year":"2018","journal-title":"J Atheroscler Thromb"},{"issue":"15","key":"10.1016\/j.jacl.2026.08.010_bib13","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jacl.2026.08.010_bib14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa0807611","article-title":"FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention","volume":"360","author":"Tonino","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jacl.2026.08.010_bib15","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacl.2016.01.005","article-title":"Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a)","volume":"10","author":"Yeang","year":"2016","journal-title":"J Clin Lipidol"},{"issue":"6","key":"10.1016\/j.jacl.2026.08.010_bib16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.jacl.2026.08.010_bib17","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","article-title":"Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia","volume":"24","author":"Dubuc","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1016\/j.jacl.2026.08.010_bib18","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jacbts.2016.06.006","article-title":"PCSK9 modulates the secretion but not the cellular uptake of lipoprotein(a) ex vivo: an effect blunted by alirocumab","volume":"1","author":"Villard","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.jacl.2026.08.010_bib19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.atherosclerosis.2017.06.026","article-title":"Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: insights from SATURN","volume":"263","author":"Puri","year":"2017","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.jacl.2026.08.010_bib20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-lowering by 50 mg\/dL may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.jacl.2026.08.010_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2022-002060","article-title":"Lp(a)HERITAGE Investigators. Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease","volume":"9","author":"Nissen","year":"2022","journal-title":"Open Heart"},{"issue":"10459","key":"10.1016\/j.jacl.2026.08.010_bib22","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"404","author":"Nordestgaard","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jacl.2026.08.010_bib23","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1399-0004.1994.tb04408.x","article-title":"Changes in Lp(a) lipoprotein and other plasma proteins during acute myocardial infarction","volume":"46","author":"Andreassen","year":"1994","journal-title":"Clin Genet"},{"issue":"2","key":"10.1016\/j.jacl.2026.08.010_bib24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3109\/00365519209088771","article-title":"Lipoprotein(a) and acute-phase proteins in acute myocardial infarction","volume":"52","author":"Slunga","year":"1992","journal-title":"Scand J Clin Lab Invest"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426004848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426004848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:09:14Z","timestamp":1789186154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426004848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":24,"alternative-id":["S1933287426004848"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.08.010","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A \u226520% increase in circulating Lp(a) after the commencement of statins, and subsequent risks of atherosclerotic cardiovascular diseases in patients with coronary artery disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}